After  successfully ‘saving’ two babies with terminal-stage acute Leukemia, Cellectis finally treated the first patient in its Phase I trial. A major milestone that could confirm the potential of its lead candidate UCART-19.

cellectis_cars_t-cell_ucart19_cytokine_crsIt’s once again a success for the French biotech company! As it announced on Monday, the first patient has been treated in the Phase 1 Trial of UCART19 in Pediatric Acute B lymphoblastic Leukemia (B-ALL). This study is taking place at the University College of London (UCL), where two previous babies have already been treated. The safety and efficiency are assessed during this trial.

But this treatment does not come alone!! It is performed ahead of planned allogeneic hematopoietic stem cell transplantation (allo-HSCT). Keep in mind that we never treat cancer with a single treatment, even if this treatment seems miraculous. It still requires parallel strategies. As Cellectis’ CEO said in our exclusive interview: CAR-T is not the miracle cure for cancer.

ADVERTISEMENT

André Choulika, CEO of Cellectis

André Choulika, CEO of Cellectis – D. Morganti.

What are the consequences of such news?

First, Cellectis received the first milestone payment from Servier (undisclosed amount), which is its partner for the development and marketing, alongside Pfizer. As you may remember, it was Servier which saved Cellectis from bankruptcy in 2015.

Another impact is that its stock become more secured, and the market capitalization is about to reach the billion euros (currently around €850M). These past few weeks, American analysts changed the rating on the shares to ‘buy, and many investors increased their position in the company. It could be a good time to invest, as prices may rise soon!


Previous post

What is Microsoft doing with this French Precision Medicine Biotech?

Next post

How did we grow from 0 to 40,000 Monthly Visitors in 18 Months?

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.